前列腺癌中的放松激酶作用:分子基础和治疗含义
Nidhi Singh1, Hannelore V Heemers1
1Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Endocrine-related cancer
|June 6, 2023
概括
新的研究探讨了改变的激酶如何驱动侵袭性前列腺癌 (CaP) 的进展和治疗耐药性. 了解这些激酶变化为针对致命的CaP的新型治疗策略提供了潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 前列腺癌 (CaP) 是男性癌症死亡的主要原因.
- 目前对转移性CaP的治疗方法提供缓解,但不能治愈,突出显示需要新的治疗点.
- 通过酸化来调节细胞信号的关键调节者酶与CaP进展和治疗耐药性有关.
研究的目的:
- 检查放松激酶活性在CaP生长,治疗耐药性和复发中的作用.
- 为了识别受 CaP 进展过程中遗传改变影响的激酶.
- 审查蛋白质组变化和与治疗耐药的CaP相关的信号.
主要方法:
- 来自临床CaP标本的下一代测序数据的分析.
- 在致命疾病进展期间对CaP样本进行 () 蛋白质组学分析.
- 对CaP中酶变化和信号通路的现有文献的审查.
主要成果:
- 基因放大,删除或突变影响的激酶的概述在CaP进展到转移性割耐药或神经内分泌CaP期间.
- 识别与耐治疗的CaP相关的蛋白质组变化及其潜在的分子机制.
- 讨论目前在CaP临床试验中的激酶抑制剂.
结论:
- 不调节的激酶活性是激进的CaP和治疗耐药性的关键驱动因素.
- 了解 CaP 基因组的改变可以为开发新型治疗策略提供信息.
- 需要进一步的研究和临床试验,以将基因组知识转化为高级前列腺癌的有效治疗方法.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Receptor Tyrosine Kinases
13.2K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.2K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K


